Volition's nu.q® discover biomarkers to be utilized in human clinical study sponsored by leading pharmaceutical company for the first time

Nu.q® discover tools provide drug developers and scientists with a range of rapid epigenetic profiling assays across pre-clinical and clinical development pathways from discovery to market ready henderson, nev. , march 4, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announces that it has signed an agreement with a leading pharmaceutical company to utilize volition's nu.q® discover biomarkers in a longitudinal phase 1/2b study.
VNRX Ratings Summary
VNRX Quant Ranking